In the third podcast, Dr. Burger discusses the added value of reporting outcomes of real-world cases in patients with HIV caused by drug-drug interactions (DDIs) with Dr. Ambrosioni and Dr. Molto.

Several databases are available for DDI management, with discrepancies often occurring between the databases. The differences may be caused by extrapolations from studied interactions to predict the DDI potential for unknown drug combinations. The relevance of the unstudied DDIs is often unknown.

Reporting the outcomes of real-world cases can determine the relevance of DDIs. The article discusses real-world cases between antiretrovirals (ARVs) and comedications reported on www.clinicalcasesDDIs.com. Twenty percent of the reported cases involve over-the-counter drugs, which are often not recorded in patient files.

The following topics will be discussed during the podcast:
- the challenges of DDI management of ARVs with comedications;
- the added value of reporting outcomes of real-world cases; and
- the underestimated risks of over-the-counter (OTC) drug use.

Listen to the podcast for all the tips and take-home messages!

Read the full article here: https://link.springer.com/article/10.1007/s40121-024-00935-0

In the second episode of this podcast series, Dr. Malone, Dr. Gómez-Lumbreras, and Dr. Burger will discuss the drug-drug interaction potential of colchicine, which may be underestimated. 

Dr. Malone’s research group did a study on real-world data on the interaction potential of colchicine. Colchicine concentration can be increased by CYP3A4 inhibitors, which may lead to toxicity and adverse events. Adverse events cases reported between 2004 and 2020 were studied for the involvement of colchicine in DDIs. In 66% of 787 studied reports, colchicine was identified as a concomitant drug.  This indicates that the reporter did not think colchicine was the cause of the adverse events mentioned in the reports. 

• Could colchicine possibly play a bigger role in DDIs than currently thought? 
• Are there any safety concerns of colchicine use combined with strong CYP3A4 inhibitors? 
• And what practical guidance is needed for the safe use of colchicine in combination with other medicines?

Listen to the second episode of DDI of the Month to find out!

In the first exciting episode of this new podcast series, Dr. Iversen and Dr. Burger will dive into DDIs with flucloxacillin, and explore the results of Dr. Iversen's research trial.

Dr. Iversen’s research group has studied the extent of induction of flucloxacillin of the CYP enzymes in healthy adults and 3D spheroid of primary human hepatocytes (PHHs). The research group performed a randomized, unblinded, two-period, cross-over, clinical pharmacokinetic (Basel) cocktail study with twelve healthy adults. During the podcast, the study will be discussed in detail.

Find out the interesting results of this study!